Videos  


Duration 6:28

Dr. Jonathan Silverberg

Associate Professor George Washington University School of Medicine and Health Sciences

 

"Upadacitinib in Moderate-to-sever Atopic Dermatitis"

Duration 3:11

Dr. Patrick Gunning

Professor of Medical Chemistry,

University of Toronto Missiauga

 

"JAKs MoA"

Duration 6:34

Dr Diamant Thaçi

Chairman and Professor, Center for Comprehensive Inflammation Medicine, University of Luebeck

 

"padacitinib Clinical Benefit-risk Profile in Moderate-to-severe Atopic Dermatitis"

Duration 5:02

Dr. Chich-Ho Hong

Clinical Assistant Professor University of British Columbia

 

"Assessment Scales, Treatment Algorithms & Targets"

Duration 6:03

Dr. Matthias Augustin

Director, Institute for Health Services Research in Dermatology and Nursing ( IVDP),

Universty Medical Center Hamburg

 

" Candidates for Systemic Therapy in Atopic Dermatitis "

Duration 6:34

Prof. Melinda Gooderham

Skin Centre for Dermatology, Ontario, Canada 

 

"Atopic Dermatitis Current U nmet Needs"

Duration 5:02

Prof. Kilian Eyerich

Department of Dermatolgy and Allergy, Technical Univeristy Munich, Germany 

 

" Atopic Dermatitis Complex Pathogenesis"

Duration 6:34

Prof. Melinda Gooderham

Skin Centre for Dermatology, Ontario, Canada 

 

"Atopic Dermatitis Burden and Comorbidities"


 

For Oman HCPs.

Department of Pharmacovigilance & Drug information.

Directorate General of pharmaceutical affairs and Drug control.

Ministry of Health, Sultanate of Oman

Phone Nos:: 22357687 / 22357686

Fax: 22358489

Email: [email protected]

Website:www.moh.gov.om

 

 

This website is intended for Gulf Healthcare Professionals

AbbVie Biopharmaceuticals GmbH.

 

Suite 2901, U Bora Tower,Business Bay, Dubai, UAE

PO Box:: 118052

OFFICE : +971 4 5506100

FAX: +971 4 5506101

Patient Safety is our Priority, we will remain always by your side. For Reporting Adverse events Please Contact.

[email protected] or Hotline: 00971564135746

JAKa-BH-00004-MC